- Home
- SFD vs ROIV Comparison
SFD vs ROIV Comparison
Compare SFD & ROIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SFD
- ROIV
- Stock Information
- Founded
- SFD 1936
- ROIV 2014
- Country
- SFD United States
- ROIV United Kingdom
- Employees
- SFD N/A
- ROIV N/A
- Industry
- SFD
- ROIV Biotechnology: Pharmaceutical Preparations
- Sector
- SFD
- ROIV Health Care
- Exchange
- SFD NYSE
- ROIV Nasdaq
- Market Cap
- SFD 7.4B
- ROIV 8.4B
- IPO Year
- SFD 2025
- ROIV N/A
- Fundamental
- Price
- SFD $19.33
- ROIV $10.60
- Analyst Decision
- SFD Strong Buy
- ROIV Strong Buy
- Analyst Count
- SFD 5
- ROIV 7
- Target Price
- SFD $28.60
- ROIV $18.08
- AVG Volume (30 Days)
- SFD 591.0K
- ROIV 4.5M
- Earning Date
- SFD 01-01-0001
- ROIV 02-10-2025
- Dividend Yield
- SFD N/A
- ROIV N/A
- EPS Growth
- SFD 14.48
- ROIV N/A
- EPS
- SFD 1.72
- ROIV N/A
- Revenue
- SFD $14,188,000,000.00
- ROIV $122,585,000.00
- Revenue This Year
- SFD N/A
- ROIV N/A
- Revenue Next Year
- SFD N/A
- ROIV N/A
- P/E Ratio
- SFD $11.25
- ROIV N/A
- Revenue Growth
- SFD N/A
- ROIV 140.04
- 52 Week Low
- SFD $18.43
- ROIV $9.76
- 52 Week High
- SFD $22.03
- ROIV $13.06
- Technical
- Relative Strength Index (RSI)
- SFD N/A
- ROIV 47.81
- Support Level
- SFD N/A
- ROIV $10.39
- Resistance Level
- SFD N/A
- ROIV $10.81
- Average True Range (ATR)
- SFD 0.00
- ROIV 0.34
- MACD
- SFD 0.00
- ROIV 0.04
- Stochastic Oscillator
- SFD 0.00
- ROIV 71.51
About SFD SMITHFIELD FOODS INC
Smithfield is the largest hog producer and pork processor in the world, processing more than 27 million hogs in fiscal 2011, with a slaughter capacity of 110,000 hogs per day. Around 55% of all pork revenue comes from value-added packaged meats, which were the focus of previous acquisitions and central to the company's long-term strategy. The firm continues to expand its European operations.
About ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.